Actively Recruiting
A Study of Patient Experiences and Health Changes in Adults With Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten Camzyos
Led by Bristol-Myers Squibb · Updated on 2024-11-07
118
Participants Needed
1
Research Sites
25 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating health changes in adults with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in real-world settings. This observational study aims to understand participants symptoms, physical limitations, quality of life, and treatment experiences over time. The study is sponsored by Bristol-Myers Squibb and collects patient-reported outcomes to monitor the impact of mavacamten treatment. Participants are adults prescribed mavacamten by their doctors for their condition. The study involves completing surveys at multiple time points including baseline, weeks 2, 4, 8, 12, 24, 30, 48, 60, 72, 84, and 96 weeks. These surveys assess symptoms using tools like the Hypertrophic Cardiomyopathy Symptom Questionnaire and the Kansas City Cardiomyopathy Questionnaire, as well as treatment status, other therapies, and health events such as surgeries or injuries. During the study, participants provide information on their symptom severity, treatment adherence, and quality of life at regular intervals. The research team collects data on medical history and any changes in symptoms or treatments. Participants also share their experiences with the CAMZYOS Risk Evaluation and Mitigation Strategy program. The study runs until June 2027, allowing long-term observation of patient outcomes while receiving mavacamten.
CONDITIONS
Brief Title
Real-world Patient Reported Outcomes Among Patients Treated With Camzyos
Research Team
B
BMS Study Connect Contact Center www.BMSStudyConnect.com
F
First line of the email MUST contain NCT # and Site #.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here